IBDEI0PG ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12557,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,12557,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,12558,0)
 ;;=250.40^^87^820^5
 ;;^UTILITY(U,$J,358.3,12558,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12558,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,12558,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,12558,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,12559,0)
 ;;=250.50^^87^820^8
 ;;^UTILITY(U,$J,358.3,12559,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12559,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,12559,1,5,0)
 ;;=5^DM Type II w/ Ophthal Manifest
 ;;^UTILITY(U,$J,358.3,12559,2)
 ;;=DM Type II w/ Ophthal Manifest^267839^362.02
 ;;^UTILITY(U,$J,358.3,12560,0)
 ;;=250.60^^87^820^6
 ;;^UTILITY(U,$J,358.3,12560,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12560,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,12560,1,5,0)
 ;;=5^DM Type II Dm with Neuropathy
 ;;^UTILITY(U,$J,358.3,12560,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,12561,0)
 ;;=250.70^^87^820^7
 ;;^UTILITY(U,$J,358.3,12561,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12561,1,4,0)
 ;;=4^250.70
 ;;^UTILITY(U,$J,358.3,12561,1,5,0)
 ;;=5^DM Type II Dm with Peripheral Vasc Dis
 ;;^UTILITY(U,$J,358.3,12561,2)
 ;;=^267843^443.81
 ;;^UTILITY(U,$J,358.3,12562,0)
 ;;=250.01^^87^820^3
 ;;^UTILITY(U,$J,358.3,12562,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12562,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,12562,1,5,0)
 ;;=5^DM Type I DM W/O Complications
 ;;^UTILITY(U,$J,358.3,12562,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,12563,0)
 ;;=272.0^^87^820^20
 ;;^UTILITY(U,$J,358.3,12563,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12563,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,12563,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,12563,2)
 ;;=Hypercholesterolemia, Pure^59973
 ;;^UTILITY(U,$J,358.3,12564,0)
 ;;=272.1^^87^820^26
 ;;^UTILITY(U,$J,358.3,12564,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12564,1,4,0)
 ;;=4^272.1
 ;;^UTILITY(U,$J,358.3,12564,1,5,0)
 ;;=5^Hypertriglyceridemia, Pure
 ;;^UTILITY(U,$J,358.3,12564,2)
 ;;=Hypertriglyceridemia, Pure^101303
 ;;^UTILITY(U,$J,358.3,12565,0)
 ;;=272.2^^87^820^23
 ;;^UTILITY(U,$J,358.3,12565,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12565,1,4,0)
 ;;=4^272.2
 ;;^UTILITY(U,$J,358.3,12565,1,5,0)
 ;;=5^Hyperlipidemia, Mixed
 ;;^UTILITY(U,$J,358.3,12565,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,12566,0)
 ;;=275.42^^87^820^19
 ;;^UTILITY(U,$J,358.3,12566,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12566,1,4,0)
 ;;=4^275.42
 ;;^UTILITY(U,$J,358.3,12566,1,5,0)
 ;;=5^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,12566,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,12567,0)
 ;;=275.41^^87^820^27
 ;;^UTILITY(U,$J,358.3,12567,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12567,1,4,0)
 ;;=4^275.41
 ;;^UTILITY(U,$J,358.3,12567,1,5,0)
 ;;=5^Hypocalcaemia
 ;;^UTILITY(U,$J,358.3,12567,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,12568,0)
 ;;=276.7^^87^820^21
 ;;^UTILITY(U,$J,358.3,12568,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12568,1,4,0)
 ;;=4^276.7
 ;;^UTILITY(U,$J,358.3,12568,1,5,0)
 ;;=5^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,12568,2)
 ;;=^60042
 ;;^UTILITY(U,$J,358.3,12569,0)
 ;;=275.2^^87^820^17
 ;;^UTILITY(U,$J,358.3,12569,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12569,1,4,0)
 ;;=4^275.2
 ;;^UTILITY(U,$J,358.3,12569,1,5,0)
 ;;=5^Hyper Or Hypomagnesemia
 ;;^UTILITY(U,$J,358.3,12569,2)
 ;;=^35626
 ;;^UTILITY(U,$J,358.3,12570,0)
 ;;=276.0^^87^820^24
 ;;^UTILITY(U,$J,358.3,12570,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12570,1,4,0)
 ;;=4^276.0
 ;;^UTILITY(U,$J,358.3,12570,1,5,0)
 ;;=5^Hypernatremia
